Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/57172
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Rodrigues, Célia Fortuna | por |
dc.contributor.author | Alves, Diana Filipa Barros | por |
dc.contributor.author | Henriques, Mariana | por |
dc.date.accessioned | 2018-12-07T08:58:20Z | - |
dc.date.available | 2018-12-07T08:58:20Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Rodrigues, Célia F.; Alves, Diana; Henriques, Mariana, Combination of Posaconazole and Amphotericin B in the Treatment of Candida glabrata Biofilms. Microorganisms, 6(4), 123, 2018 | por |
dc.identifier.issn | 2076-2607 | por |
dc.identifier.uri | https://hdl.handle.net/1822/57172 | - |
dc.description.abstract | Candidemia cases have been increasing, especially among immunosuppressed patients. Candida glabrata is one of the most resistant Candida species, especially to the azole drugs, resulting in a high demand for therapeutic alternatives. The minimum inhibitory concentration (MIC), minimum fungicidal concentration (MFC), and minimum biofilm eradication concentration (MBEC) were determined for posaconazole (Pcz) and amphotericin B (AmB). The drug combinations of both drugs were evaluated on pre-formed biofilms of C. glabrata ATCC 2001, through XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay, colony forming units (CFU), crystal violet, and the fractional inhibitory concentration index (FICI). C. glabrata revealed higher susceptibility and biofilm reduction in the presence of AmB alone, but both drugs revealed a good capacity in the biomass elimination. In the majority of the tested combinations, the interactions were defined as indifferent (FICI 4). The combination of the two drugs does not seem to bring a clear advantage in the treatment of biofilms of C. glabrata. | por |
dc.description.sponsorship | This study was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UID/BIO/04469/2013 unit and COMPETE 2020 (POCI-01-0145-FEDER-006684) and BioTecNorte operation (NORTE-01-0145-FEDER-000004) funded by the European Regional Development Fund under the scope of Norte2020—Programa Operacional Regional do Norte and Célia F. Rodrigues’ (SFRH/BD/93078/2013) PhD grant. | por |
dc.language.iso | eng | por |
dc.publisher | MDPI Publishing | por |
dc.relation | info:eu-repo/grantAgreement/FCT/5876/147337/PT | por |
dc.relation | info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F93078%2F2013/PT | por |
dc.rights | openAccess | por |
dc.subject | Candida | por |
dc.subject | Posaconazole | por |
dc.subject | Amphotericin B | por |
dc.subject | Biofilms | por |
dc.subject | Matrix | por |
dc.subject | Antifungal drug | por |
dc.subject | Antifungal combination | por |
dc.subject | Resistance | por |
dc.subject | Candida glabrata | por |
dc.title | Combination of Posaconazole and Amphotericin B in the treatment of Candida glabrata biofilms | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | http://www.mdpi.com/journal/microorganisms | por |
dc.comments | CEB49300 | por |
oaire.citationStartPage | 123 | por |
oaire.citationIssue | 4 | por |
oaire.citationVolume | 6 | por |
dc.date.updated | 2018-12-06T19:47:49Z | - |
dc.identifier.doi | 10.3390/microorganisms6040123 | por |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Microorganisms | por |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_49300_1.pdf | 1,6 MB | Adobe PDF | Ver/Abrir |